Committee reviews statute governing medication for opioid use disorder in correctional facilities

The Restrictions Committee on Jan. 23 reviewed the statutory framework that governs medication for opioid use disorder (MOUD) inside Vermont correctional facilities and how the Department of Corrections (DOC) and contractors must coordinate with community providers at reentry.

The session focused on Title 28, Chapter 11 provisions addressing medical care of inmates and a companion section that specifically cross-references Title 18’s definition of medication for opioid use disorder. Committee members and Department of Health staff emphasized that MOUD in correctional settings must align with community standards, be medically necessary, and be paired with counseling and behavioral therapies.

Katie McGlynn, Office of Legislative Counsel, walked the committee through the statute. She highlighted the opening requirement that DOC provide “health care for inmates in accordance with prevailing medical standards,” and explained screening and assessment steps: an inmate admitted for 14 consecutive days must receive a physical assessment and must be screened for substance use disorder, including opioids, within 24 hours of admission. McGlynn said the statute authorizes continuation of medications that an inmate is taking pursuant to a valid prescription, “including buprenorphine, methadone, or other MOUD medication,” pending evaluation by a licensed clinician.

Tony Fallon, clinical services manager, Department of Health Division of Substance Use, described operational details and the state’s hub-and-spoke structure for opioid treatment. Fallon said Vermont has seven federally designated “hubs” that dispense methadone and serve as high-intensity treatment sites, with additional “spoke” providers prescribing buprenorphine in primary-care settings. Fallon said a hub is federally licensed and highly regulated by SAMHSA and the DEA; correctional facilities are not hubs, but the state has operational agreements so hubs or local clinics can dispense or ship medication and DOC can receive it for inmates.

On induction and transfers: the statute allows an inmate who screens positive for opioid use disorder to commence buprenorphine in a correctional facility if a provider deems it medically necessary and the inmate chooses to begin MOUD. The law also permits transfer from buprenorphine to methadone if a methadone prescriber deems methadone medically necessary and the inmate chooses the transfer. The committee was told the statutory text does not authorize initial induction onto methadone inside a correctional facility; methadone induction typically requires a federally licensed hub and different operational arrangements.

The committee discussed discharge and reentry requirements. For non-MOUD prescriptions, the statute requires DOC or its contractor to provide an exiting offender with not less than a 28-day supply of medication when clinically appropriate. By contrast, for MOUD the statute requires DOC or its contractor to provide a “legally permissible supply” at discharge sufficient to bridge the person until community-based follow-up can occur; committee members said that language was intentionally different to avoid giving a long take‑home supply of controlled medication and to prioritize linking inmates to a hub or spoke for continued treatment. McGlynn summarized: regular chronic medications (heart, insulin, blood pressure) were intended to receive the 28‑day supply, while MOUD was carved out for a shorter, legally permissible bridge supply.

The statute also requires reentry planning steps: DOC or its contractor must identify a licensed health-care provider or substance-use treatment program and start scheduling intake appointments so the person can continue care in the community. DOC and its contractors may employ or contract with a caseworker or health navigator to assist scheduling. Fallon said the health system also supports open-access hub appointments, emergency-department buprenorphine protocols, and pharmacy callbacks so short-notice releases (for example, detainees released after a few days) can still be bridged to care.

Committee members raised operational questions that statute does not fully resolve. They asked how conflicts over “medical necessity” are decided; Fallon said such disagreements are rare, that Wellpath (DOC’s medical contractor) generally coordinates with the Department of Health for consultations, and that the Vermont Prescription Monitoring System and prior medical records are used to verify community prescriptions. The committee also discussed diversion risks, staffing constraints for twice‑daily dosing when needed, and the higher regulatory burden that prevents correctional facilities from serving as methadone hubs.

On outcomes, Fallon said treatment and coordinated reentry planning have reduced post-release overdoses compared with pre-MOUD baselines; he noted the period of highest overdose risk after release is the first two weeks. Fallon also provided capacity and scale context: Vermont operates seven hubs (with one under construction in Bennington) and uses federal block-grant funds and Medicaid billing to support services; he said the correctional system serves hundreds of people on MOUD on any given day and estimated “somewhere between 650 and 800” people in correctional settings receive MOUD on a typical day out of roughly 1,400 people incarcerated.

No formal changes to statute were taken at the meeting. Committee members and Department staff agreed the committee should use the statutory baseline reviewed at this session to evaluate any future bills that propose modifications to MOUD delivery, discharge supplies, or reentry procedures.

Members flagged several practical follow-ups the committee may want if it reviews legislation: clarifying the statutory carve-out that MOUD discharge supplies differ from the 28‑day rule for other medications; whether statutory language needs to explicitly permit specific reentry navigator roles; and whether facility-level capabilities or contracts should be adjusted to reduce transports for methadone dosing.